Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...